Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Phase 1 Terminated
40 enrolled
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Phase 1 Recruiting
120 enrolled
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Phase 1 Recruiting
70 enrolled
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
96 enrolled
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Phase 1 Withdrawn
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Phase 1 Completed
27 enrolled
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
19 enrolled
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Phase 1 Completed
24 enrolled
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
Phase 1 Completed